Add BrightSurf on Google Email

Unveiling the biology behind nonalcoholic fatty liver disease

Researchers at EPFL have identified a key player in the development of nonalcoholic fatty liver disease (NAFLD), a condition characterized by excessive fat accumulation in the liver. The study found that impaired SUMOylation of nuclear receptor LRH-1 promotes NAFLD, highlighting potential new treatments and biomarkers for the disease.

SourceEcole Polytechnique Fédérale de Lausanne·JournalJournal of Clinical Investigation·DateJan 17, 2017

Antioxidant may protect offspring of obese mothers from fatty liver disease

New research published in The FASEB Journal suggests that pyrroloquinoline quinone (PQQ) may prevent the development of nonalcoholic fatty liver disease in offspring. PQQ, a naturally occurring antioxidant found in soil and foods, was shown to protect against liver damage and inflammation in mice fed high-fat diets.

Newer tests could cut hep C diagnosis steps in half

Researchers found that several commercially available tests for hepatitis C virus core antigen are highly sensitive and specific, potentially replacing the current two-test screening process with a single test. This could streamline care in low- and middle-income countries where HCV is prevalent, but patients are often lost to follow-up.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·DateJun 20, 2016

Non-alcoholic fatty liver disease shown to affect the development of coronary artery calcification

A new study published at The International Liver Congress reveals that non-alcoholic fatty liver disease (NAFLD) is associated with the development of coronary artery calcification. In patients without existing CAC, NAFLD significantly accelerated atherosclerosis progression, while in those with existing CAC, it did not affect disease ...

Updates in liver disease research: Do you want the good or bad news?

Recent studies confirm that NAFLD worsens heart disease and increases serum levels of cardiovascular risk markers. Additionally, a large population sample found a significant association between psychological distress and liver disease mortality. Meanwhile, inpatient mortality for cirrhosis patients has decreased by 41% in the U.S., at...

SourceAmerican Gastroenterological Association·JournalGASTROENTEROLOGY·DateApr 22, 2015

Receptor may be key to treating nonalcoholic fatty liver disease

A team of researchers found that inhibiting the intestinal farnesoid X receptor with drugs like tempol and antibiotics can prevent nonalcoholic fatty liver disease in mice. This discovery highlights the complex role of gut microbes in human health and potential targets for treating metabolic disorders.

SourcePenn State·JournalJournal of Clinical Investigation·DateDec 15, 2014